Methylprednisolone

Physicians from American Oncology Network Selected to Present at the American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Jeudi, décembre 21, 2023
Physician, Research, Rituximab, Hodgkin lymphoma, Health, Doctor of Philosophy, Addition, Society, ASH, Abstract, AON, Clinical trial, Methylprednisolone, FACP

Each year, over 5,000 scientific abstracts undergo a meticulous and thorough peer review process, with only a select few earning acceptances for oral and poster presentations at the annual meeting and exposition.

Key Points: 
  • Each year, over 5,000 scientific abstracts undergo a meticulous and thorough peer review process, with only a select few earning acceptances for oral and poster presentations at the annual meeting and exposition.
  • The selected abstracts epitomize crucial and innovative research in the field.
  • “As physicians, we are on the front lines of patient care, and our research is an extension of that commitment.
  • “Their commitment to research and the betterment of patient care is a testament to the caliber of physicians we have at AON.

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Retrieved on: 
Mercredi, décembre 20, 2023
CSF, Immunosuppression, Partnership, ALS, GM1, Aes, Krabbe disease, FTD, Loss, ICM, PASG, Clinical trial, Plasma, Inflammation, Methylprednisolone, AAV, Toxicity, GRN, Patient, Frontotemporal dementia, Safety, Cell biology, Hepatotoxicity, MLD, DRG, Pharmaceutical industry

Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.

Key Points: 
  • Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
  • "We are proud to announce initial clinical data from our upliFT-D clinical trial, which showcases the ability of PBFT02 to elevate CSF progranulin to supraphysiologic levels at the lowest tested dose, Dose 1, up to six months post-treatment.
  • The upliFT-D clinical trial evaluates PBFT02 as a single dose delivered via intra-cisterna magna (ICM) injection.
  • These strategic priorities and clinical milestones underscore Passage Bio's dedication to advancing cutting-edge, one-time genetic medicines and protecting patients and families against loss in neurodegenerative conditions.

TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing

Retrieved on: 
Jeudi, juillet 6, 2023
MIC, National Transportation Safety Board, Frontiers, HLA, CSO, Immune tolerance, Clinical trial, Antibody, DSA, Fungal infection, Transplant, Incidence, EUR, Patient, Immune system, Series, Autoimmune disease, Methylprednisolone, Kidney transplantation, University Hospital Heidelberg, Leukapheresis, BMJ Open, Autoimmunity, Dentistry, Medical device, Immunology

Furthermore, the company is publishing 5-year follow-up data of a Phase I trial of its MIC-Lx cell therapy.

Key Points: 
  • Furthermore, the company is publishing 5-year follow-up data of a Phase I trial of its MIC-Lx cell therapy.
  • Our preclinical studies also demonstrate great potential in autoimmune disease"
    On the back of these promising results, TolerogenixX also reported a EUR 7 million second closing of its Series A financing round now totaling EUR 11.6 million.
  • "We are very pleased that we were able to add EUR 7 million to our Series A financing round," Schaier said.
  • "In the current financing environment, this is a further validation of our approach, enabling us to successfully complete our Phase II program."

Cancer Cachexia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, avril 28, 2023
Pharmaceutical, Health, Oncology, Methylprednisolone, Dexamethasone, Government, Cancer, Cachexia, Appetite, Therapy, Prevalence, Patient, Megestrol acetate, Non-governmental organization, LBM, Digestion, Pharmaceutical industry, Dietary supplement

The global cancer cachexia market size reached US$ 2.0 Billion in 2022.

Key Points: 
  • The global cancer cachexia market size reached US$ 2.0 Billion in 2022.
  • This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia.
  • Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth.
  • The publisher provides an analysis of the key trends in each sub-segment of the global cancer cachexia market report, along with forecasts at the global, regional and country level from 2023-2028.

Worldwide Cancer Cachexia Industry to 2027 - Featuring Aphios, Artelo Biosciences and AVEO Pharmaceuticals Among Others - ResearchAndMarkets.com

Retrieved on: 
Jeudi, mai 26, 2022
Health, Oncology, Inflammation, Conditional sentence, TB, Cachexia, Tuberculosis, Non-governmental organization, Patient, COPD, Government, LBM, Weight gain, Digestion, Nipple stimulation, COVID-19, Methylprednisolone, Industry, Appetite, Awareness, Multiple sclerosis, Chronic obstructive pulmonary disease, Therapy, HIV, Prevalence, Cancer, Dexamethasone, Megestrol acetate, Pharmaceutical industry

Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy.

Key Points: 
  • Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy.
  • This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia.
  • How has the global cancer cachexia market performed so far and how will it perform in the coming years?
  • What is the structure of the global cancer cachexia market and who are the key players?

Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association

Retrieved on: 
Jeudi, mai 12, 2022
Biotechnology, Health, Stem Cells, Pharmaceutical, Clinical Trials, Rash, Itolizumab, Risk, Nausea, Private Securities Litigation Reform Act, Disease, CD6, EDGAR, HSCT, Nasdaq, Adolescence, McMillan, European Hematology Association, Patient, Skin discoloration, ALCAM, IV, Mortality, Adult, Feedback, Volunteering, Trial of the century, EHA, Degenerative disease, Methylprednisolone, Irritation, Partnership, Alopecia areata, Forward-looking statement, Safety, Vomiting, THE, GVHD, EQUIP, Therapy, Phase 3, SEC, Itch, Jaundice, Diarrhea, Cancer, Immunoglobulin G, Pharmaceutical industry, Vaccine

For more information and access to the abstract, visit the EHA Open Access Library .

Key Points: 
  • For more information and access to the abstract, visit the EHA Open Access Library .
  • Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Retrieved on: 
Vendredi, mars 4, 2022
Oncology, Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, EQUIP, Risk, Private Securities Litigation Reform Act, Harvard Medical School, Patient, Adult, HSCT, GVHD, Population, Asthma, Forward-looking statement, Vomiting, Disease, Itolizumab, IV, Safety, CR, FDA, Methylprednisolone, Degenerative disease, Alopecia areata, CD6, Nausea, ORR, SEC, Cancer, Rash, Trial of the century, EDGAR, Adolescence, Diarrhea, Jaundice, Mortality, Partnership, McMillan, Itch, Nasdaq, Incidence, Irritation, Skin discoloration, Feedback, Therapy, Pharmaceutical industry, Vaccine, Medicine, the EQUATOR Study, Equillium, THE EQUATOR STUDY, EQUILLIUM

The initiation of this pivotal study marks a major milestone for Equillium to assess itolizumabs potential as a life-changing advancement for patients suffering from acute GVHD, said Bruce Steel, chief executive officer of Equillium.

Key Points: 
  • The initiation of this pivotal study marks a major milestone for Equillium to assess itolizumabs potential as a life-changing advancement for patients suffering from acute GVHD, said Bruce Steel, chief executive officer of Equillium.
  • Our Phase 3 study is supported by the compelling results from our EQUATE study demonstrating rapid and durable complete responses in high-risk acute GVHD patients.
  • Hematologists and transplantation specialists have highlighted their enthusiasm for itolizumab as a potential therapeutic option and we are optimistic for these patients as we launch the EQUATOR study.
  • If successful in the EQUATOR study, itolizumab could result in the first approval of a novel therapeutic in the first-line treatment of acute GVHD, potentially transformative in the field.

Advaita Bioinformatics and Henry Ford Health System Discover that a Well-Known Drug Helps Prevent Worst COVID-19 Outcomes

Retrieved on: 
Mardi, avril 28, 2020
Software, Biotechnology, Pharmaceutical, Health, Data management, Infectious diseases, Technology, Clinical trials, Glucocorticoids, RTT, Drugs, Medicine, Chemistry, Dexamethasone, Methylprednisolone, HFHS, Severe acute respiratory syndrome-related coronavirus, Prednisone, Henry Ford Health System, Glucocorticoids, RTT, Drugs, Medicine, Chemistry, Dexamethasone, Methylprednisolone, HFHS, Severe acute respiratory syndrome-related coronavirus, Prednisone, Henry Ford Health System, Glucocorticoids, RTT, Drugs, Medicine, Chemistry, Dexamethasone, Methylprednisolone, HFHS, Severe acute respiratory syndrome-related coronavirus, Prednisone, Henry Ford Health System

This was confirmed in a clinical study at Henry Ford Health System (HFHS).

Key Points: 
  • This was confirmed in a clinical study at Henry Ford Health System (HFHS).
  • The drug was identified using Advaitas advanced AI platform, iPathwayGuide, which showed the necessity of modulating the immune response to SARS-CoV-2.
  • For instance, methylprednisolone was predicted to revert COVID-19-induced changes, while other steroids, such as prednisone or dexamethasone, were not.
  • The fantastic work done at Henry Ford by Dr. Ramesh and his colleagues proved that our approach has clinical value.

Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol® (Methylprednisolone)

Retrieved on: 
Lundi, octobre 28, 2019
Pharmaceuticals policy, Pharmaceutical industry, Articles, Health, Glucocorticoids, Methylprednisolone, RTT, Generic drug, Life sciences

ST. LOUIS, Oct. 28, 2019 /PRNewswire/ --Oakrum Pharma, LLC ("Oakrum"), in collaboration with SunGen Pharma, LLC ("SunGen"), announced today the U.S. launch and commercial shipment of a generic version of Medrol (Methylprednisolone) in 4 mg tablets.

Key Points: 
  • ST. LOUIS, Oct. 28, 2019 /PRNewswire/ --Oakrum Pharma, LLC ("Oakrum"), in collaboration with SunGen Pharma, LLC ("SunGen"), announced today the U.S. launch and commercial shipment of a generic version of Medrol (Methylprednisolone) in 4 mg tablets.
  • Jim Huang, Ph.D., Co-CEO of SunGen, stated, "We are pleased to partner with the Oakrum for this launch.
  • SunGen Pharma, LLC is a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products.
  • SunGen has business partnerships with many US-based generic pharmaceutical companies to develop, manufacture, and sell several pharmaceutical products in the US.

MSN Labs/Novadoz Pharmaceuticals Early Success Continues With FDA Approval Of Generic Abiraterone

Retrieved on: 
Lundi, juillet 15, 2019
Drugs, Hormones, Organic compounds, Alcohols, Androstanes, CYP17A1 inhibitors, Pyridines, Abiraterone acetate, Abiraterone, Prostate cancer, Methylprednisolone, Food and Drug Administration

PISCATAWAY, N.J., July 15, 2019 /PRNewswire/ --MSN Labs, the parent company of Novadoz Pharmaceuticals, was granted FDA approval to market Abiraterone Acetate 250mg tablets, a generic version of Janssen Pharmaceuticals'product Zytiga, on July 9th.

Key Points: 
  • PISCATAWAY, N.J., July 15, 2019 /PRNewswire/ --MSN Labs, the parent company of Novadoz Pharmaceuticals, was granted FDA approval to market Abiraterone Acetate 250mg tablets, a generic version of Janssen Pharmaceuticals'product Zytiga, on July 9th.
  • This FDA approval marks the ninth since March 2018, when Novadoz began commercial operations as MSN Labs' U.S sales and marketing affiliate for their finished dosage forms.
  • MSN's approval for Abiraterone Acetate 250mg tablets, in the class of oncology drugs indicated for the treatment of prostate cancer when used with a steroid medication (prednisone or methylprednisolone).
  • "The approval of generic Abiraterone is a significant for our organization as it continues to fill our portfolio with important products, most specifically those used in the oncology class.